Royalty Non Operating Income Net Other vs Net Income Analysis

RPRX Stock

USD 27.41 1.02 3.87%

Royalty PharmaPlc financial indicator trend analysis is much more than just breaking down Royalty PharmaPlc prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Royalty PharmaPlc is a good investment. Please check the relationship between Royalty PharmaPlc Non Operating Income Net Other and its Net Income accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Royalty PharmaPlc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Royalty Stock please use our How to Invest in Royalty PharmaPlc guide.

Non Operating Income Net Other vs Net Income

Non Operating Income Net Other vs Net Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Royalty PharmaPlc Non Operating Income Net Other account and Net Income. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Royalty PharmaPlc's Non Operating Income Net Other and Net Income is -0.07. Overlapping area represents the amount of variation of Non Operating Income Net Other that can explain the historical movement of Net Income in the same time period over historical financial statements of Royalty PharmaPlc, assuming nothing else is changed. The correlation between historical values of Royalty PharmaPlc's Non Operating Income Net Other and Net Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Operating Income Net Other of Royalty PharmaPlc are associated (or correlated) with its Net Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income has no effect on the direction of Non Operating Income Net Other i.e., Royalty PharmaPlc's Non Operating Income Net Other and Net Income go up and down completely randomly.

Correlation Coefficient

-0.07

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Non Operating Income Net Other

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Royalty PharmaPlc financial statement analysis. It represents the amount of money remaining after all of Royalty PharmaPlc operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Most indicators from Royalty PharmaPlc's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Royalty PharmaPlc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Royalty PharmaPlc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Royalty Stock please use our How to Invest in Royalty PharmaPlc guide.At this time, Royalty PharmaPlc's Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to rise to 0.00 in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.06 in 2024.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	51.4M	5.7M	5.1M	4.8M
Interest Income	53.5M	78.3M	72.3M	45.0M

Depreciation And Amortization Interest Income

Royalty PharmaPlc fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Accounts Payable	Cash	Other Assets	Common Stock Shares Outstanding	Short Term Investments	Inventory	Other Current Assets	Total Liab	Treasury Stock	Common Stock	Property Plant Equipment	Intangible Assets	Net Tangible Assets	Retained Earnings	Total Current Assets	Short Long Term Debt Total	Net Debt	Non Current Assets Total	Non Currrent Assets Other	Long Term Debt	Cash And Short Term Investments
Total Assets		0.78	0.59	0.98	-0.33	0.8	0.67	0.54	0.53	0.32	0.39	0.39	0.95	-0.24	0.21	-0.36	-0.17	0.93	0.92	0.88	0.06	0.7	0.86	0.41	0.13	-0.44
Other Current Liab	0.78		0.62	0.76	-0.24	0.42	0.87	0.19	0.23	0.29	0.16	0.25	0.81	-0.27	0.42	-0.3	0.13	0.7	0.6	0.93	-0.04	0.15	0.42	0.16	0.03	-0.06
Total Current Liabilities	0.59	0.62		0.53	-0.17	0.26	0.81	0.27	0.18	0.27	0.1	0.83	0.7	-0.25	0.42	-0.25	0.13	0.65	0.56	0.72	0.25	0.27	0.36	-0.1	-0.19	0.04
Total Stockholder Equity	0.98	0.76	0.53		-0.32	0.83	0.59	0.45	0.48	0.29	0.53	0.29	0.91	-0.25	0.26	-0.35	-0.13	0.91	0.91	0.82	-0.1	0.67	0.81	0.4	0.01	-0.51
Other Liab	-0.33	-0.24	-0.17	-0.32		-0.3	-0.2	-0.71	-0.27	-0.29	-0.09	-0.08	-0.33	-0.71	-0.1	0.98	-0.2	-0.33	-0.32	-0.26	-0.01	-0.27	-0.29	-0.25	-0.05	0.25
Accounts Payable	0.8	0.42	0.26	0.83	-0.3		0.18	0.62	0.68	-0.18	0.38	0.17	0.71	-0.23	0.06	-0.25	-0.32	0.74	0.79	0.45	-0.05	0.83	0.83	0.78	0.05	-0.87
Cash	0.67	0.87	0.81	0.59	-0.2	0.18		0.23	0.14	0.46	0.0	0.47	0.79	-0.27	0.51	-0.29	0.19	0.7	0.58	0.93	0.23	0.15	0.33	-0.12	0.13	0.2
Other Assets	0.54	0.19	0.27	0.45	-0.71	0.62	0.23		0.63	0.03	-0.16	0.3	0.55	0.28	-0.03	-0.66	-0.19	0.56	0.57	0.34	0.46	0.75	0.69	0.64	0.45	-0.52
Common Stock Shares Outstanding	0.53	0.23	0.18	0.48	-0.27	0.68	0.14	0.63		-0.2	-0.12	0.25	0.46	-0.07	-0.22	-0.18	-0.39	0.59	0.58	0.27	-0.03	0.6	0.74	0.72	0.07	-0.57
Short Term Investments	0.32	0.29	0.27	0.29	-0.29	-0.18	0.46	0.03	-0.2		0.32	0.24	0.27	0.35	-0.01	-0.39	0.09	0.27	0.27	0.49	0.07	0.0	0.22	-0.56	0.13	0.52
Inventory	0.39	0.16	0.1	0.53	-0.09	0.38	0.0	-0.16	-0.12	0.32		-0.09	0.29	-0.08	0.3	-0.14	0.11	0.37	0.47	0.19	-0.61	0.28	0.22	-0.17	-0.52	-0.32
Other Current Assets	0.39	0.25	0.83	0.29	-0.08	0.17	0.47	0.3	0.25	0.24	-0.09		0.39	-0.01	-0.12	-0.12	-0.16	0.37	0.32	0.43	0.44	0.26	0.43	-0.07	-0.1	0.12
Total Liab	0.95	0.81	0.7	0.91	-0.33	0.71	0.79	0.55	0.46	0.27	0.29	0.39		-0.34	0.46	-0.37	-0.03	0.96	0.92	0.91	0.15	0.67	0.73	0.34	0.16	-0.39
Treasury Stock	-0.24	-0.27	-0.25	-0.25	-0.71	-0.23	-0.27	0.28	-0.07	0.35	-0.08	-0.01	-0.34		-0.42	-0.68	0.09	-0.32	-0.3	-0.26	-0.01	-0.2	-0.08	-0.11	0.0	0.2
Common Stock	0.21	0.42	0.42	0.26	-0.1	0.06	0.51	-0.03	-0.22	-0.01	0.3	-0.12	0.46	-0.42		-0.18	0.53	0.42	0.37	0.37	-0.18	0.07	-0.21	-0.19	-0.22	-0.12
Property Plant Equipment	-0.36	-0.3	-0.25	-0.35	0.98	-0.25	-0.29	-0.66	-0.18	-0.39	-0.14	-0.12	-0.37	-0.68	-0.18		-0.3	-0.36	-0.35	-0.33	-0.03	-0.26	-0.28	-0.14	-0.04	0.17
Intangible Assets	-0.17	0.13	0.13	-0.13	-0.2	-0.32	0.19	-0.19	-0.39	0.09	0.11	-0.16	-0.03	0.09	0.53	-0.3		-0.07	-0.12	0.03	-0.21	-0.34	-0.45	-0.37	-0.27	0.21
Net Tangible Assets	0.93	0.7	0.65	0.91	-0.33	0.74	0.7	0.56	0.59	0.27	0.37	0.37	0.96	-0.32	0.42	-0.36	-0.07		0.98	0.83	0.02	0.74	0.78	0.34	0.05	-0.46
Retained Earnings	0.92	0.6	0.56	0.91	-0.32	0.79	0.58	0.57	0.58	0.27	0.47	0.32	0.92	-0.3	0.37	-0.35	-0.12	0.98		0.75	-0.02	0.81	0.82	0.36	0.04	-0.54
Total Current Assets	0.88	0.93	0.72	0.82	-0.26	0.45	0.93	0.34	0.27	0.49	0.19	0.43	0.91	-0.26	0.37	-0.33	0.03	0.83	0.75		0.17	0.37	0.59	0.09	0.19	-0.03
Short Long Term Debt Total	0.06	-0.04	0.25	-0.1	-0.01	-0.05	0.23	0.46	-0.03	0.07	-0.61	0.44	0.15	-0.01	-0.18	-0.03	-0.21	0.02	-0.02	0.17		0.27	0.2	0.11	0.77	0.18
Net Debt	0.7	0.15	0.27	0.67	-0.27	0.83	0.15	0.75	0.6	0.0	0.28	0.26	0.67	-0.2	0.07	-0.26	-0.34	0.74	0.81	0.37	0.27		0.84	0.6	0.3	-0.73
Non Current Assets Total	0.86	0.42	0.36	0.81	-0.29	0.83	0.33	0.69	0.74	0.22	0.22	0.43	0.73	-0.08	-0.21	-0.28	-0.45	0.78	0.82	0.59	0.2	0.84		0.58	0.28	-0.53
Non Currrent Assets Other	0.41	0.16	-0.1	0.4	-0.25	0.78	-0.12	0.64	0.72	-0.56	-0.17	-0.07	0.34	-0.11	-0.19	-0.14	-0.37	0.34	0.36	0.09	0.11	0.6	0.58		0.29	-0.82
Long Term Debt	0.13	0.03	-0.19	0.01	-0.05	0.05	0.13	0.45	0.07	0.13	-0.52	-0.1	0.16	0.0	-0.22	-0.04	-0.27	0.05	0.04	0.19	0.77	0.3	0.28	0.29		0.05
Cash And Short Term Investments	-0.44	-0.06	0.04	-0.51	0.25	-0.87	0.2	-0.52	-0.57	0.52	-0.32	0.12	-0.39	0.2	-0.12	0.17	0.21	-0.46	-0.54	-0.03	0.18	-0.73	-0.53	-0.82	0.05

Click cells to compare fundamentals

Royalty PharmaPlc Account Relationship Matchups

Royalty PharmaPlc fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	12.4B	21.1B	17.5B	16.8B	16.4B	17.2B
Other Current Liab	9.2M	297.1M	165.6M	161.4M	146.2M	153.5M
Total Current Liabilities	333.4M	307.9M	171.3M	1.2B	161.4M	132.4M
Total Stockholder Equity	6.1B	9.9B	5.8B	5.6B	6.5B	6.9B
Accounts Payable	11.2M	10.8M	5.6M	7.9M	15.2M	15.9M
Cash	283.7M	1.0B	1.5B	1.7B	477.0M	343.9M
Other Assets	10.9B	5.1B	13.7B	13.5B	15.5B	16.3B
Common Stock Shares Outstanding	365.9M	375.5M	414.8M	438.0M	602.9M	409.1M
Short Term Investments	509.5M	983M	1.3B	717.0M	18.3M	17.4M
Other Current Assets	92K	8.6M	6.6M	90.5M	3.8M	5.8M
Total Liab	6.3B	6.1B	7.3B	7.3B	6.3B	6.6B
Intangible Assets	51.7M	28.7M	5.7M	14.5M	1.8M	1.7M
Net Tangible Assets	6.1B	4.8B	5.8B	5.6B	6.5B	3.7B
Retained Earnings	2.8B	1.9B	2.3B	2.0B	2.5B	1.4B
Total Current Assets	832.1M	2.7B	2.9B	2.6B	1.3B	1.6B
Short Long Term Debt Total	6.2B	5.8B	7.1B	7.1B	6.1B	7.1B
Net Debt	6.0B	4.8B	5.6B	5.4B	5.7B	5.9B
Non Current Assets Total	11.6B	13.3B	14.6B	14.3B	15.1B	14.2B
Non Currrent Assets Other	88.0M	28.6M	4.1M	15.1M	14.1B	14.8B
Long Term Debt	6.0B	5.8B	7.1B	6.1B	6.1B	6.8B
Cash And Short Term Investments	793.2M	2.0B	2.8B	2.4B	495.3M	470.5M
Net Receivables	38.8M	39.2M	68.3M	36.6M	775.1M	813.8M
Long Term Debt Total	6.0B	5.8B	7.1B	6.1B	7.0B	6.9B
Liabilities And Stockholders Equity	12.4B	21.1B	17.5B	16.8B	16.4B	17.5B
Non Current Liabilities Total	6.0B	5.8B	7.1B	6.1B	6.1B	6.9B
Other Stockholder Equity	(4.3M)	7.9B	3.5B	3.7B	4.0B	3.5B
Net Invested Capital	12.3B	10.6B	12.9B	12.7B	12.7B	13.2B
Long Term Investments	11.5B	13.0B	14.4B	14.1B	15.1B	14.1B
Accumulated Other Comprehensive Income	2.1M	34.4M	16.5M	63K	72.5K	68.8K
Net Working Capital	498.7M	2.4B	2.7B	1.4B	1.1B	1.3B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
BAC	Bank of America
GM	General Motors

When determining whether Royalty PharmaPlc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Royalty PharmaPlc's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Royalty Pharmaplc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Royalty Pharmaplc Stock:

How To Invest In Royalty

Details

Is Royalty Stock a good investment?

Details

What is Royalty PharmaPlc's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Royalty PharmaPlc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Royalty Stock please use our How to Invest in Royalty PharmaPlc guide.

You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Complementary Tools for Royalty Stock analysis

When running Royalty PharmaPlc's price analysis, check to measure Royalty PharmaPlc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty PharmaPlc is operating at the current time. Most of Royalty PharmaPlc's value examination focuses on studying past and present price action to predict the probability of Royalty PharmaPlc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty PharmaPlc's price. Additionally, you may evaluate how the addition of Royalty PharmaPlc to your portfolios can decrease your overall portfolio volatility.

	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios
	Equity Valuation Check real value of public entities based on technical and fundamental data
	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Stocks Directory Find actively traded stocks across global markets
	Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
	Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum

Is Royalty PharmaPlc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Royalty PharmaPlc. If investors know Royalty will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Royalty PharmaPlc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.99)

Dividend Share

0.81

Earnings Share

1.78

Revenue Per Share

4.993

Quarterly Revenue Growth

(0.17)

The market value of Royalty PharmaPlc is measured differently than its book value, which is the value of Royalty that is recorded on the company's balance sheet. Investors also form their own opinion of Royalty PharmaPlc's value that differs from its market value or its book value, called intrinsic value, which is Royalty PharmaPlc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Royalty PharmaPlc's market value can be influenced by many factors that don't directly affect Royalty PharmaPlc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Royalty PharmaPlc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Royalty PharmaPlc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Royalty PharmaPlc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Royalty Non Operating Income Net Other vs Net Income Analysis

Non Operating Income Net Other vs Net Income

Non Operating Income Net Other vs Net Income Correlation Analysis

Correlation Coefficient

Non Operating Income Net Other

Net Income

Royalty PharmaPlc fundamental ratios Correlations

Royalty PharmaPlc Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Royalty PharmaPlc fundamental ratios Accounts

Also Currently Popular

Complementary Tools for Royalty Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 0.98	Total Assets
Property Plant Equipment	+ 0.98	Other Liab
Retained Earnings	+ 0.98	Net Tangible Assets
Net Tangible Assets	+ 0.96	Total Liab
Total Liab	+ 0.95	Total Assets
Net Tangible Assets	+ 0.93	Total Assets

Cash And Short Term Investments	- 0.87	Accounts Payable
Cash And Short Term Investments	- 0.82	Non Currrent Assets Other
Cash And Short Term Investments	- 0.73	Net Debt
Treasury Stock	- 0.71	Other Liab
Other Assets	- 0.71	Other Liab
Property Plant Equipment	- 0.68	Treasury Stock